Drug Trial Radar · NCT06836037
A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)
Last checked: Nov 19, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Sep 5, 2022
Primary completion
Feb 2, 2023
Study completion Feb 2, 2023
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this study is to learn about the safety and whether people tolerate a study medicine called efinopegdutide. The study will also measure what happens to efinopegdutide in a healthy person's body over time.
Conditions
- Healthy
Interventions
EfinopegdutideDrug
Subcutaneous injection
PlaceboDrug
placebo matching efinopegdutide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 112 days
- Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 78 days
- Maximum Plasma Concentration (Cmax) of Efinopegdutide- single doseTime frame: At designated time points up to 35 days
- Time to Maximum Plasma Concentration (Tmax) of Efinopegdutide- single doseTime frame: At designated time points up to 35 days
- Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Efinopegdutide- single doseTime frame: At designated timepoints up to 35 days
- Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-inf) of Efinopegdutide- single doseTime frame: At designated timepoints up to 35 days
- Terminal half life (t1/2) of Efinopegdutide- single doseTime frame: At designated timepoints up to 35 days
- Apparent Clearance (CL) of Efinopegdutide- single doseTime frame: At designated timepoints up to 35 days
- Volume of Distribution (Vz) of Efinopegdutide- single doseTime frame: At designated timepoints up to 35 days
- Maximum Plasma Concentration (Cmax) of Efinopegdutide- multiple doseTime frame: At designated time points up to 112 days
- Minimum Plasma Concentration (Cmin) of Efinopegdutide- multiple doseTime frame: At designated time points up to 112 days
- Time to Maximum Plasma Concentration (Tmax) of Efinopegdutide- multiple doseTime frame: At designated time points up to 112 days
- Terminal half life (t1/2) of Efinopegdutide- multiple doseTime frame: At designated timepoints up to 112 days
- Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Efinopegdutide-multiple doseTime frame: At designated timepoints up to 112 days
- Apparent Clearance (CL) of Efinopegdutide- multiple doseTime frame: At designated timepoints up to 112 days
- Volume of Distribution at Steady State (Vss) of Efinopegdutide- multiple doseTime frame: At designated timepoints up to 112 days
- Area Under the Concentration-Time Curve to the end of the dosing period (AUC 0-tau)of Efinopegdutide- multiple doseTime frame: At designated timepoints up to 78 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital,Fudan University-Dep. of Clinical Pharmacology (Site 0001)
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.